journal article·2025-12-02

Designing nanomedicine to overcome therapeutic challenges in pregnancy

Tamar Gross Lev, Assaf Zinger

Nature Reviews Bioengineering· Volume 4· Issue 1
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Pregnancy and Medication Impact · Pregnancy and preeclampsia studies · Pharmacological Effects and Toxicity Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (15)

Show source-provided references
1. Feghali, M., Venkataramanan, R. & Caritis, S. Pharmacokinetics of drugs in pregnancy. Semin. Perinatol. 39, 512–519 (2015).10.1053/j.semperi.2015.08.003 ↗
2. Sharma, A., Sah, N., Kannan, S. & Kannan, R. M. Targeted drug delivery for maternal and perinatal health: challenges and opportunities. Adv. Drug Deliv. Rev. 177, 113950 (2022).10.1016/j.addr.2021.113950 ↗
3. Figueroa-Espada, C. G., Hofbauer, S., Mitchell, M. J. & Riley, R. S. Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy. Adv. Drug Deliv. Rev. 160, 244–261 (2020).10.1016/j.addr.2020.09.006 ↗
4. Shojaei, S. et al. Dynamic placenta-on-a-chip model for fetal risk assessment of nanoparticles intended to treat pregnancy-associated diseases. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166131 (2021).10.1016/j.bbadis.2021.166131 ↗
5. Scaffidi, J., Mol, B. & Keelan, J. The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy. BJOG 124, 132–140 (2017).10.1111/1471-0528.14151 ↗
6. Chambers, C. D., Polifka, J. E. & Friedman, J. M. Drug safety in pregnant women and their babies: ignorance not bliss. Clin. Pharmacol. Ther. 83, 181–183 (2008).10.1038/sj.clpt.6100448 ↗
7. Cardonick, E. & Iacobucci, A. Use of chemotherapy during human pregnancy. Lancet Oncol. 5, 283–291 (2004).10.1016/S1470-2045(04)01466-4 ↗
8. Galbally, M., Snellen, M. & Power, J. Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects. Ther. Adv. Drug Saf. 5, 100–109 (2014).10.1177/2042098614522682 ↗
9. Costantine, M. M. Physiologic and pharmacokinetic changes in pregnancy. Front. Pharmacol. 5, 65 (2014).10.3389/fphar.2014.00065 ↗
10. Al-Enazy, S., Ali, S., Albekairi, N., El-Tawil, M. & Rytting, E. Placental control of drug delivery. Adv. Drug Deliv. Rev. 116, 63–72 (2017).10.1016/j.addr.2016.08.002 ↗
11. Huang, Y., Wang, J., Jiang, K. & Chung, E. J. Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions. J Control. Release 334, 127–137 (2021).10.1016/j.jconrel.2021.04.016 ↗
12. Spada, A., Emami, J., Tuszynski, J. A. & Lavasanifar, A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol. Pharm. 18, 1862–1894 (2021).10.1021/acs.molpharmaceut.1c00046 ↗
13. Gao, W., Chan, J. & Farokhzad, O. C. pH-responsive nanoparticles for drug delivery. Mol. Pharm. 7, 1913–1920 (2010).10.1021/mp100253e ↗
14. Zinger, A. et al. Enhancing inflammation targeting using tunable leukocyte-based biomimetic nanoparticles. ACS Nano 15, 6326–6339 (2021).10.1021/acsnano.0c05792 ↗
15. Zinger, A. Unleashing the potential of cell biomimetic nanoparticles: strategies and challenges in their design and fabrication for therapeutic applications. J. Control. Release 358, 591–600 (2023).10.1016/j.jconrel.2023.04.040 ↗